BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines bRUKINSA — Global Revenue Growth YoY (%) (%)
Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases
Latest, Q2 2026
31.4%
Period ended Jun 30, 2026
Change on a year earlier
-17.6 pts
49.0% in Q2 2025
History
17 quarters
Since Q3 2021
Sources
17
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — Global Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 31.4% | -17.6 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 38.3% | -23.8 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 50.8% | -42.2 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 49.0% | -57.8 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 62.1% | -69.0 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 93.0% | -37.0 pts | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 106.8% | -32.6 pts | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 131.1% | +28.5 pts | Form 10-Q (filed 2024-05-08) ↗ |
| Q3 2023 | Sep 30, 2023 | 130.0% | -6.2 pts | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 139.4% | -64.1 pts | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 102.6% | -269.4 pts | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 101.0% | -277.0 pts | Form 8-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 136.2% | -183.8 pts | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 203.5% | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 372.0% | – | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 378.0% | – | Form 8-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 320.0% | – | Form 10-Q (filed 2021-11-04) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — Global Revenue Growth YoY (%) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_brukinsa_ww_yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.